@article{CJCR891,
author = {Jing Yu and Jun Ren and Li-jun Di and Guo-hong Song and Yu-lin Zhu and Jie Zhang and Xu Liang and Li Che and Han-fang Jiang and Jun Jia and Chun-rong Zhang},
title = {Mobilization of Peripheral Blood Stem Cells Using Regimen Combining Docetaxel with Granulocyte Colony-stimulating Factor in Breast Cancer Patients},
journal = {Chinese Journal of Cancer Research},
volume = {23},
number = {1},
year = {2012},
keywords = {},
abstract = {Objective: To evaluate the effectiveness and safety of the mobilization of peripheral blood hematopoietic stem cells by combining docetaxel with granulocyte colony-stimulating factor (G-CSF) in breast cancer patients.
Methods: A total of 57 breast cancer patients were treated with docetaxel 120 mg/m2. When the white blood cell (WBC) count decreased to 1.0×109/L, patients were given G-CSF 5 μg/kg daily by subcutaneous injection until the end of apheresis. Peripheral blood mononuclear cells (MNC) were isolated by Cobe Spectra Apheresis System. The percentage of CD34+ cell was assayed by flow cytometry.
Results: At a median 6 of days (range 3-8) after the administration of docetaxel, the median WBC count decreased to 1.08×109/L (range 0.20-2.31). The median duration of G-CSF mobilization was 3 days (range 2-7). The MNC collection was conducted 8-12 days (median 10 days) after docetaxel treatment. The median MNC was 5.35×108/kg (range 0.59-14.07), the median CD34+ cell count was 2.43×106/kg (range 0.16-16.69). The CD34+ cell count was higher than 1.00×106/kg in 47 of 57 cases (82.46%) and higher than 2.00×106/kg in 36 cases (63.16%). The CD34+ cell count was higher than 2.00×106/kg in 27 collections (23.68%). The MNC count and the CD34+ cell count were correlated with the bottom of WBC after docetaxel chemotherapy (r=0.364, 0.502, P=0.005, 0.000). The CD34+ cell count was correlated with the MNC count (r=0.597, P=0.000). The mobilization and apheresis were well tolerated in all patients. Mild perioral numbness and numbness of hand or feet were observed in 3 cases. No serious adverse events were reported.
Conclusion: Mobilization of peripheral blood hematopoietic stem cell by combining docetaxel with G-CSF was effective and safety in breast cancer patients.},
issn = {1993-0631}, url = {https://cjcr.amegroups.org/article/view/891}
}